WGRX
Wellgistics Health, Inc.
Medical - Distribution
Market Cap$8M
5Y Perf.-96.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
WGRX vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
MCK
McKesson Corporation
Medical - Distribution
Market Cap$92.15B
5Y Perf.+17.5%
WGRX vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | WGRX | MCK |
|---|---|---|
| Industry | Medical - Distribution | Medical - Distribution |
| Market Cap | $8M | $92.15B |
| Revenue (TTM) | $6M | $403.43B |
| Net Income (TTM) | $-73M | $4.76B |
| Gross Margin | 4.1% | 3.6% |
| Operating Margin | -12.1% | 1.5% |
| Forward P/E | — | 19.3x |
| Total Debt | $25M | $7.39B |
| Cash & Equiv. | $1M | $5.69B |
WGRX vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
WGRX
MCK
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| Wellgistics Health,… (WGRX) | 100 | 3.3 | -96.7% |
| McKesson Corporation (MCK) | 100 | 117.5 | +17.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WGRX vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MCK leads in 6 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
WGRX
Wellgistics Health, Inc.
The Specific-Use Pick
In this particular matchup, WGRX is outpaced on most metrics by others in the set.
Best for: healthcare exposure
MCK
McKesson Corporation
The Income Pick
MCK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 17 yrs, beta 0.04, yield 0.4%
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 348.1% 10Y total return vs WGRX's -97.7%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MCK | 16.2% revenue growth vs WGRX's -91.8% |
| Quality / Margins | MCK | 1.2% margin vs WGRX's -13.0% |
| Stability / Safety | MCK | Beta 0.04 vs WGRX's 0.96 |
| Dividends | MCK | 0.4% yield; 17-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | MCK | +4.6% vs WGRX's -98.0% |
| Efficiency (ROA) | MCK | 5.7% ROA vs WGRX's -138.4%, ROIC 5.4% vs -32.2% |
WGRX vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
WGRX vs MCK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMCKLAGGINGWGRX
WGRXWellgistics Health, I…
0leads
MCKMcKesson Corporation
4leads
6 Total Categories
CATEGORYLEADERvs WGRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MCK5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MCK5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
MCK6/6
Risk & VolatilityBeta, volatility, and downside exposure
MCK2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MCK leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK is the larger business by revenue, generating $403.4B annually — 71797.5x WGRX's $6M. MCK is the more profitable business, keeping 1.2% of every revenue dollar as net income compared to WGRX's -13.0%. On growth, MCK holds the edge at +6.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | WGRXWellgistics Healt… | MCKMcKesson Corporat… |
|---|---|---|
| RevenueTrailing 12 months | $6M | $403.4B |
| EBITDAEarnings before interest/tax | -$65M | $6.8B |
| Net IncomeAfter-tax profit | -$73M | $4.8B |
| Free Cash FlowCash after capex | -$7M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +4.1% | +3.6% |
| Operating MarginEBIT ÷ Revenue | -12.1% | +1.5% |
| Net MarginNet income ÷ Revenue | -13.0% | +1.2% |
| FCF MarginFCF ÷ Revenue | -130.5% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -80.9% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -11.8% | +37.0% |
MCK leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — WGRX and MCK each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | WGRXWellgistics Healt… | MCKMcKesson Corporat… |
|---|---|---|
| Market CapShares × price | $8M | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $32M | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.68x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.28x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.75x |
| EV / EBITDAEnterprise value multiple | — | 18.74x |
| Price / SalesMarket cap ÷ Revenue | 0.44x | 0.26x |
| Price / BookPrice ÷ Book value/share | 0.68x | — |
| Price / FCFMarket cap ÷ FCF | — | 17.63x |
Evenly matched — WGRX and MCK each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MCK leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-11 for WGRX.
| Metric | WGRXWellgistics Healt… | MCKMcKesson Corporat… |
|---|---|---|
| ROE (TTM)Return on equity | -10.8% | +3.0% |
| ROA (TTM)Return on assets | -138.4% | +5.7% |
| ROICReturn on invested capital | -32.2% | +5.4% |
| ROCEReturn on capital employed | -73.4% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | 3.73x | — |
| Net DebtTotal debt minus cash | $24M | $1.7B |
| Cash & Equiv.Liquid assets | $1M | $5.7B |
| Total DebtShort + long-term debt | $25M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | -10.95x | 33.79x |
MCK leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
MCK leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $232 for WGRX. Over the past 12 months, MCK leads with a +4.6% total return vs WGRX's -98.0%. The 3-year compound annual growth rate (CAGR) favors MCK at 27.3% vs WGRX's -71.5% — a key indicator of consistent wealth creation.
| Metric | WGRXWellgistics Healt… | MCKMcKesson Corporat… |
|---|---|---|
| YTD ReturnYear-to-date | -79.7% | -8.5% |
| 1-Year ReturnPast 12 months | -98.0% | +4.6% |
| 3-Year ReturnCumulative with dividends | -97.7% | +106.4% |
| 5-Year ReturnCumulative with dividends | -97.7% | +286.9% |
| 10-Year ReturnCumulative with dividends | -97.7% | +348.1% |
| CAGR (3Y)Annualised 3-year return | -71.5% | +27.3% |
MCK leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
MCK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than WGRX's 0.96 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MCK currently trades 75.3% from its 52-week high vs WGRX's 1.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | WGRXWellgistics Healt… | MCKMcKesson Corporat… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.96x | 0.04x |
| 52-Week HighHighest price in past year | $7.04 | $999.00 |
| 52-Week LowLowest price in past year | $0.08 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +1.3% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 31.2 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 13.8M | 757K |
MCK leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
MCK is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | WGRXWellgistics Healt… | MCKMcKesson Corporat… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $1006.50 |
| # AnalystsCovering analysts | — | 31 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 17 |
| Dividend / ShareAnnual DPS | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
MCK leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallMcKesson Corporation (MCK)Leads 4 of 6 categories
Loading custom metrics...
WGRX vs MCK: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is WGRX or MCK a better buy right now?
McKesson Corporation (MCK) offers the better valuation at 29.
2x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate McKesson Corporation (MCK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — WGRX or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -97. 7% for Wellgistics Health, Inc. (WGRX). Over 10 years, the gap is even starker: MCK returned +348. 1% versus WGRX's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — WGRX or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus Wellgistics Health, Inc. 's 0. 96β — meaning WGRX is approximately 2124% more volatile than MCK relative to the S&P 500.
04Which is growing faster — WGRX or MCK?
On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14.
9% year-over-year, compared to -116. 7% for Wellgistics Health, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — WGRX or MCK?
McKesson Corporation (MCK) is the more profitable company, earning 0.
9% net margin versus -37. 8% for Wellgistics Health, Inc. — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus -33. 9% for WGRX. At the gross margin level — before operating expenses — WGRX leads at 9. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — WGRX or MCK?
In this comparison, MCK (0.
4% yield) pays a dividend. WGRX does not pay a meaningful dividend and should not be held primarily for income.
07Is WGRX or MCK better for a retirement portfolio?
For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
04), +348. 1% 10Y return). Both have compounded well over 10 years (MCK: +348. 1%, WGRX: -97. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between WGRX and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: WGRX is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(WGRX: -80.9% · MCK: 6.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.